This application requests continued support for the "Vanderbilt Infection Pathogenesis and Epidemiology Research" (VIPER) Training Program. The objective is to prepare postdoctoral fellows for careers as investigators in infectious diseases. Training is in basic laboratory research into pathogenesis using molecular and cellular methods, as well as in patient-oriented research and epidemiology / outcomes research. Training is primarily through participation in the preceptors'translational research projects in viral pathogenesis, immune pathogenesis, bacterial pathogenesis, epidemiology / outcomes /patient-oriented research that are directed toward goals of chemotherapy and vaccine development. There is broad expertise among the Program faculty and a clear, focused strength on translationally-relevant HIV and mycobacterial pathogenesis research. Participating faculty are based mainly in the Infectious Disease Divisions of Medicine and Pediatrics and the Department of Microbiology and Immunology. The Program has a strong track record of joint, interactive training of post-M.D. fellows from both Medicine and Pediatrics. It also includes some post-Ph.D. trainees. There is extensive collaboration among mentors, and most are senior. Interactions between post-M.D. fellows, post-Ph.D. fellows, and Microbiology and Immunology graduate students are substantial. The program selects candidates with research career potential from M.D. applicants for ID fellowship, and from qualified PhD post-doctoral fellows. It provides training, experience, supervision, resources, and role models for independent academic careers. Long-term success is maximized by a customized research / career plan for each trainee with a dedicated mentor, while being guided and supervised by an advisory committee and the Program Director. Training is carried out in the laboratory and/or clinical research setting of the preceptor. A course in responsible conduct of research is required. A minimum of two years of research training is required for all, and physicians complete a clinical year of ID fellowship before starting VIPER training.
The continuing epidemics of HIV and tuberculosis, as well as emerging and re-emerging infections of major public health importance indicate a substantial and significant need for additional researchers who can develop vaccines and treatments for such infections.
|Budge, Philip J; Dorkenoo, Ameyo M; Sodahlon, Yao K et al. (2014) Ongoing surveillance for lymphatic filariasis in Togo: assessment of alternatives and nationwide reassessment of transmission status. Am J Trop Med Hyg 90:89-95|
|Kodaman, Nuri; Pazos, Alvaro; Schneider, Barbara G et al. (2014) Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proc Natl Acad Sci U S A 111:1455-60|
|Eilertson, Brandon; Maruri, Fernanda; Blackman, Amondrea et al. (2014) High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 58:3270-5|
|Budge, Philip J; Griffin, Marie R; Edwards, Kathryn M et al. (2014) Impact of home environment interventions on the risk of influenza-associated ARI in Andean children: observations from a prospective household-based cohort study. PLoS One 9:e91247|
|Thomsen, Isaac P; Dumont, Ashley L; James, David B A et al. (2014) Children with invasive Staphylococcus aureus disease exhibit a potently neutralizing antibody response to the cytotoxin LukAB. Infect Immun 82:1234-42|
|Castilho, Jessica L; Melekhin, Vlada V; Sterling, Timothy R (2014) Sex differences in HIV outcomes in the highly active antiretroviral therapy era: a systematic review. AIDS Res Hum Retroviruses 30:446-56|
|van der Heijden, Yuri F; Maruri, Fernanda; Blackman, Amondrea et al. (2013) Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. Int J Antimicrob Agents 42:232-7|
|Maruri, Fernanda; Sterling, Timothy R; Kaiga, Anne W et al. (2012) A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67:819-31|
|Pettit, A C; Kaltenbach, L A; Maruri, F et al. (2011) Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting. Int J Tuberc Lung Dis 15:906-11|
|Pettit, April C; Jenkins, Cathy A; Stinnette, Samuel E et al. (2011) Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr 57:305-10|
Showing the most recent 10 out of 39 publications